Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 176 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Migraine Clear all
Completed Phase 2 Interventional

Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine

NCT00567086
View directory record Official record
Conditions
Migraine
Interventions
TEZAMPANEL
Drug
Lead sponsor
TorreyPines Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2007 · Synced Sep 7, 2026, 3:15 AM EDT
Recruiting Phase 2 Interventional

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

NCT07646613
View directory record Official record
Conditions
Migraine
Interventions
ASY202, Placebo
Combination Product
Lead sponsor
Aspeya, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Walnut Creek, California • Orlando, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

NCT04360044
View directory record Official record
Conditions
Migraine, Cannabis, THC, CBD
Interventions
THC ~5%, CBD ~12%, THC ~5% and CBD ~12%, Sham Cannabis
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults

NCT00573170
View directory record Official record
Conditions
Migraine Disorders, Migraine, Acute
Interventions
TREXIMET®, Butalbital-containing Combination Medications (BCM), placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
107
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2010 · Synced Sep 7, 2026, 3:15 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks

NCT03159000
View directory record Official record
Conditions
Migraine
Interventions
Saline, lidocaine/bupivacaine
Drug · Combination Product
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

NCT00724815
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101 - Sumatriptan iontophoretic transdermal patch, Placebo
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

NCT03836664
View directory record Official record
Conditions
Migraine
Interventions
Timolol, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 7, 2026, 3:15 AM EDT
Recruiting Phase 3 Interventional

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07674654
View directory record Official record
Conditions
Acute Migraine
Interventions
Elismetrep, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
113
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack

NCT00530517
View directory record Official record
Conditions
Migraine Headache
Interventions
Intraject Sumatriptan
Device
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Chicago, Illinois • Springfield, Missouri • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

NCT02745392
View directory record Official record
Conditions
Acute Migraine
Interventions
ZP-Zolmitriptan, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

NCT03877718
View directory record Official record
Conditions
Migraine, Pain, Nausea, Vomiting, Aura
Interventions
Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
Drug · Other
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transnasal Therapy for Acute Migraine Attack

NCT04129567
View directory record Official record
Conditions
Migraine Disorders
Interventions
Humidified oxygen, Dry oxygen, Humidified air, Dry air
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational Results available

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

NCT06680206
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Triptans
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

NCT05509400
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Stamford, Connecticut • Lake City, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Not listed Phase 4 Interventional

IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine

NCT02664116
View directory record Official record
Conditions
Migraine Headache
Interventions
Diclofenac postassium powder for oral solution and placebo injection, Ketorolac intramuscular injection and placebo oral solution
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Greater Occipital Nerve Block With Bupivacaine for Acute Migraine

NCT02665273
View directory record Official record
Conditions
Migraine
Interventions
Greater occipital nerve block, Bupivacaine
Procedure · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 7, 2026, 3:15 AM EDT
Not listed Phase 2 Interventional

Study of Low-level Laser Therapy in the Acute Treatment of Migraine

NCT02969642
View directory record Official record
Conditions
Migraine Headache
Interventions
Argus Migraine Treatment device
Device
Lead sponsor
The San Francisco Clinical Research Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Acute Treatment Trial in Adult Subjects With Migraines

NCT03872453
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
82
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Not applicable Interventional Results available

Timolol Eye Drops in the Treatment of Acute Migraine Headache

NCT02630719
View directory record Official record
Conditions
Migraine
Interventions
Timolol eye drops, Artificial tears
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 7, 2026, 3:15 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine

NCT01653522
View directory record Official record
Conditions
Migraine Disorders, Headache, Migraine, Migraine, Migraine Headache, Migraine With Aura, Migraine Without Aura, Headache Disorders, Primary
Interventions
Triptan, Doxycycline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Maximizing Outcomes in Treating Acute Migraine

NCT03896009
View directory record Official record
Conditions
Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 4 Interventional Results available

Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack

NCT01230411
View directory record Official record
Conditions
Episodic Migraine
Interventions
saline placebo, Ibuprofen
Other · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

NCT00442221
View directory record Official record
Conditions
Migraine Headaches
Interventions
Sumatriptan and Naproxen sodium
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2007 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

NCT01667679
View directory record Official record
Conditions
Migraine, Headaches
Interventions
100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally, OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 7, 2026, 3:15 AM EDT